Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2023.05.053
- Author:
Ya-Ru WANG
1
;
Yan-Ping MA
2
Author Information
1. Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
2. Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.E-mail: myanp18@163.com.
- Publication Type:Journal Article
- Keywords:
bortezomib;
drug resistance;
multiple myeloma
- MeSH:
Humans;
Bortezomib/therapeutic use*;
Multiple Myeloma/pathology*;
Proteasome Inhibitors/pharmacology*;
Prognosis;
Plasma Cells/pathology*;
Drug Resistance, Neoplasm;
Antineoplastic Agents/pharmacology*;
Cell Line, Tumor
- From:
Journal of Experimental Hematology
2023;31(5):1584-1587
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a common plasma cell malignancy, accounting for the second largest hematological malignancy. Proteasome inhibitors represented by bortezomib (BTZ) have been the main treatment for patients with newly diagnosed and relapsed or refractory myeloma in nearly two decades. Although BTZ has improved the prognosis of MM patients, MM remains incurable in most patients, mainly because MM cells become resistant to BTZ. This review is to better understand the mechanism of MM resistance to BTZ and explore possible new therapeutic strategies.
